According to “the American Society of Clinical Oncology 2007 update of Recommendations for the Use of Tumor Markers in Breast Cancer", only three biomarkers, including ERα, PR and HER2 expression and/or amplification, are recommended for routine clinical use for every patient with primary invasive breast cancer [33], [34]. Here, ERBB2 is linked to breast cancer.